Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 8:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 338 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Comparative Effectiveness Study Clear all

Conditions: Depression
Interventions: Duloxetine, Escitalopram, BMS-820836 Placebo, BMS-820836; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 976 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 48
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Chino, California + 41 more

Conditions: Stroke, Transient Ischemic Attack
Interventions: Nursing care model; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Dementia
Interventions: Health System-based Dementia Care, Community-based Dementia Care, Usual Care; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: Not listed
Enrollment: 2,176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Winston-Salem, North Carolina • Wilkes-Barre, Pennsylvania • Galveston, Texas + 1 more

Conditions: Cancer
Interventions: caspofungin acetate, liposomal amphotericin B; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Cardiovascular Events, Type2 Diabetes, Renal Disease
Interventions: SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA, 2nd generation SU; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 781,430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Opioid Use Disorder
Interventions: Sublingual buprenorphine with naloxone, Injectable subcutaneous buprenorphine; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 952 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 25
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Long Beach, California + 21 more

Conditions: Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia, Ventilator Associated Pneumonia
Interventions: ATM-AVI, MTZ, MER, COL; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 5
States / cities: Tucson, Arizona • Torrance, California • Springfield, Illinois

Conditions: Serious Bacterial Infection
Interventions: ATM-AVI, BAT; Combination Product · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Maternal Oxygen Use in Labor
Interventions: Liberal use of maternal oxygen, Indicated use of maternal oxygen; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 844 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sciatica, Radiculopathy
Interventions: epidural steroid injection, Sham epidural steroid injection, Gabapentin, Placebo gabapentin; Procedure · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 17 Years to 100 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: San Diego, California • Baltimore, Maryland • Bethesda, Maryland

Conditions: Hemianopia, Homonymous
Interventions: Biofeedback Fixation Training, Saccadic Reading Training; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 89 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Venous Thromboembolism, Pulmonary Embolus, Deep Vein Thrombosis
Interventions: Not listed
Lead sponsor: Scripps Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: San Diego, California

Conditions: Endothelial Dysfunction, Metabolic Syndrome, Chronic Inflammation
Interventions: UCMSCs, BMMSCs, Placebo; Biological · Other
Lead sponsor: Joshua M Hare; Other
Eligibility: 21 Years to 95 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Substance Use Disorders
Interventions: Adherence to ASAM protocols, Non-adherence to ASAM protocols; Other
Lead sponsor: RTI International; Other
Eligibility: 19 Years and older
Enrollment: 991 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate; Drug
Lead sponsor: Fisons; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Boston, Massachusetts

Conditions: Pediculus Capitis Infestation
Interventions: Spinosad, Permethrin 1%; Drug
Lead sponsor: ParaPRO LLC; Industry
Eligibility: 6 Months and older
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Ormond Beach, Florida • West Palm Beach, Florida • Indianapolis, Indiana + 3 more

Conditions: Dental Plaque Induced Gingivitis, Dental Plaque
Interventions: Oral B Healthy Clean Manual Toothbrush, BURST Sonic Oral Care, Philipps Sonicare DiamondClean 300 Series; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Distal Aortic Dissection, Dissection, Aortic Acute, Acute Type B Aortic Dissection (Uncomplicated)
Interventions: BMT+TEVAR, BMT; Device · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Infection, Pulmonary Complications
Interventions: amphotericin B deoxycholate, voriconazole; Drug
Lead sponsor: European Organisation for Research and Treatment of Cancer - EORTC; Network
Eligibility: 12 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Wethersfield, Connecticut

Conditions: Smoking, Pain, Smoking Cessation
Interventions: Smoking Cessation plus CBI, Smoking Cessation Standard; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: West Haven, Connecticut • Leeds, Massachusetts

Conditions: Surgical Hemostasis
Interventions: rThrombin, bovine thrombin; Biological · Drug
Lead sponsor: ZymoGenetics; Industry
Eligibility: 18 Years and older
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 29
States / cities: Birmingham, Alabama • Arcadia, California • Glendale, California + 21 more

Conditions: Non Small Cell Lung Cancer NSCLC
Interventions: Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + carboplatin, Pemetrexed + cisplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 16
States / cities: Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 13 more

Conditions: Wounds and Injuries
Interventions: AR/101, Placebo; Drug
Lead sponsor: Arava Bio Tech Ltd.; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cardiovascular Disease
Interventions: EVARREST™ Fibrin Sealant Patch, Topical hemostat; Biological
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 9
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Baltimore, Maryland + 6 more

Search by objective public record fields.

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

Improving Coordination and Transitions of Care in Stroke Patients

D-CARE - The Dementia Care Study: A Pragmatic Clinical Trial of Health System-Based Versus Community-Based Dementia Care

Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder

A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.

Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria

The Comparative Effectiveness of Liberal Versus Restricted Maternal Administration of Oxygen During Labor

Steroids Versus Gabapentin

Comparative Efficacy of Saccadic and Biofeedback Training in Homonymous Hemianopia

Multicenter Registry for Comparative Effectiveness Analysis of Venous Thromboembolism in Trauma Patients

Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.

Patient Centered Assessment and Substance Use Disorder Treatment Study (PCAST)

A Double-Blind Group Comparative Study To Evaluate the Long-Term Safety and Effectiveness of Two Different Doses of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients With Multiple Episodes of PCP

Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice

A Comparative Study of Electric Toothbrushes for the Efficacy Plaque Removal and the Effect on Plaque Accumulation and Gingivitis.

ACute Uncomplicated Type b Aortic Dissection: Endovascular Repair vs. Best Medical Therapy

Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis

Pain and Smoking Study

Study of Recombinant Human Thrombin for Bleeding During Surgery

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

Safety and Efficacy of AR/101 in Accelerating Re-epithelialization of Split Thickness Wounds

The Fibrin Pad CV Phase III Study